In vivo biological response following low-dose interleukin-2 in complete remission B-cell non-Hodgkin's lymphoma patients

European Journal of Haematology

Volumn 57, Issue 1, 1996, Pages 33-37

  Vecchi, Angela ^a   Cavanna, Luigi ^b   Avanzini, Paolo ^c   Callea, Vincenzo ^d   Velardi, Andrea ^e   Albi, Nicola ^e   Tartoni, Pierluigi ^a   Bensi, Laura ^a   Valentini, Paola ^a   Longo, Rosina ^a   Sacchi, Stefano ^a,f  

^a UNIVERSITY OF MODENA AND REGGIO EMILIA   (Italy)

^b Division of Internal Medicine   (Italy)

^c Arcispedale Santa Maria Nuova   (Italy)

^d University of Perugia ^*  (Italy)

^e UNIVERSITY OF PERUGIA   (Italy)

^f UNIVERSITY OF MODENA AND REGGIO EMILIA   (Italy)

Author keywords

non Hodgkin's lymphoma; Outpatient immunotherapy; rIL 2

Indexed keywords

BLEOMYCIN; CYTARABINE; LEUFERON; METHOTREXATE; PREDNISONE; RECOMBINANT INTERLEUKIN 2; UNCLASSIFIED DRUG;

ARTICLE; B CELL LYMPHOMA; CANCER COMBINATION CHEMOTHERAPY; CLINICAL ARTICLE; CLINICAL PROTOCOL; DOSE RESPONSE; DRUG EFFICACY; EDEMA; FEVER; HUMAN; LYMPHOCYTE COUNT; MAINTENANCE THERAPY; NONHODGKIN LYMPHOMA; PRIORITY JOURNAL; SUBCUTANEOUS DRUG ADMINISTRATION; TREATMENT OUTCOME;

EID: 8944239880     PISSN: 09024441     EISSN: None     Source Type: Journal    
DOI: 10.1111/j.1600-0609.1996.tb00486.x     Document Type: Article

References (43)

1. FISHER RI, DEVITA JR VT, HUBBARD SM, et al. Diffuse aggressive lymphomas: increased survival after alternating flexible sequences of ProMACE and MOPP chemotherapy. Ann Intern Med 1983: 98: 304-309.
2. SKARIN AT, CANELLOS GP, ROSENTHAL DS. Improved prognosis of diffuse histiocytic and undifferentiated lymphoma by use of high dose methotrexate alternating with standard agents (M-BACOD). J Clin Oncol 1983: 1: 91-98.
3. KLIMO P, CONNORS JM. MACOP-B chemotherapy for the treatment of diffuse large cell lymphoma. Ann Intern Med 1985: 102: 596-602.
4. COLTMAN CA, DAHLBERG S, JONES SE. CHOP is curative in thirty percent of patients with large cell lymphoma: a twelve-year Southwest Oncology Group follow-up. In: SKARIN AT, ed. Update on treatment for diffuse Large Cell Lymphoma. New York, NY: Park Row: 1986: 71-77.
5. COIFFIER B, BRYON PA, FRENCH M, et al. Intensive chemotherapy in aggressive lymphomas: updated results of LNH-80 protocol and prognostic factors affecting response and survival. Blood 1987: 70: 1394-1399.
6. BOYD DB, COLEMAN M, PAPISH SW. et al. COPBLAM III: infusional combination chemotherapy for diffuse large-cell lymphoma. J Clin Oncol 1988: 6: 425-433.
7. SHIPP MA, YEAP BY, HARRINGTON DP, et al. The M-BACOD combination chemotherapy regimen in large-cell lymphoma: analysis of the complete trial and comparison with the M-BACOD regimen. J Clin Oncol 1990: 8: 84-93.
8. HOSKINS PJ, NG V, SPINELLI JJ, KLIMO P, CONNORS JM. Prognostic variables in patients with diffuse large-cell lymphoma treated with MACOP-B. J Clin Oncol 1991: 9: 220-226.
9. LONGO DL, DEVITA JR VT, DUFFEY PL, et al. Superiority of ProMACE-CytaBOM over ProMACE-MOPP in the treatment of advanced diffuse aggressive lymphoma: results of a prospective randomized trial. J Clin Oncol 1991: 9: 25-38.
10. MCMASTER ML, GREER JP, WOLFF SN, et al. Results of treatment with high intensity, brief duration chemotherapy in poor prognosis non-Hodgkin's lymphoma. Cancer 1991: 68: 233-241.
11. CAROTENUTO M, FEDERICO M, AVANZINI P, et al. A multi-center randomized trial of two different ProMACE-CytaBOM derived protocols in aggressive non-Hodgkin's lymphomas (NHL). A preliminary report. Leuk Lymph 1992: 7: 25-28.
12. DUMONTET C, BASTION Y, FELMAN P. Long-term outcome and quality of life in aggressive lymphoma patients treated with the LNH-80 regimen. Ann Oncol 1992: 3: 639-644.
13. BRUGIATELLI M, FEDERICO M, GOBBI PG, et al. Epidoxorubicin vs Idarubicin containing regimens in intermediate and high grade non-Hodgkin's lymphoma: preliminary results of a multicentric randomized trial. Haematologica 1993: 78: 306-312.
14. SILINGARDI V, FEDERICO M, CAVANNA L, et al. Pro MECE-CytaBOM vs MACOP-B in advanced aggressive non-Hodgkin's lymphoma: long term results of a multicenter study of the Italian Lymphoma Study Group (GISL). Leuk Lymph 1994: 17: 313-320.
15. PRICE CGA, ROHATINER AZS., STEWARD W, et al. Interferon-α2b in the treatment of follicular lymphoma: preliminary results of a trial in progress. Ann Oncol 1991: 2 (suppl):2: 141-145.
16. HAGENBEEK A, CARDE P, SOMERS R, et al. Maintenance of remission with human recombinant α-2 interferon (Roferon-A) in patients with stages III and IV low grade malignant non Hodgkin's lymphoma. Results from a prospective, randomised phase III clinical trial in 331 patients. Blood 1992: 80 (suppl 1a): 288.
17. LIBERATI AM, DI CLEMENTE F, FILIPPO S, et al. Cyclophosphamide, epidoxorubicin, vincristine and prednisone therapy, with or without IFN-α2a in low-grade malignancy non Hodgkin's lymphoma. Fifth International Conference on Malignant Lymphoma, Lugano, 9-12 June, 1993, a 150.
18. MCLAUGHLIN P, CABANILLAS F, HAGEMEISTER FB, et al. CHOP-Bleo plus interferon for stage IV low-grade lymphoma. Ann Oncol 1993: 4: 205-211.
19. PETERSON BA, PETRONI G, OKEN MM, OZER H. Cyclophosphamide versus cyclophosphamide plus interferon alfa-2b in follicular low grade lymphomas: a preliminary report of an intergroup trial (CALGB 8691 and EST 7486). J Clin Oncol 1993: 12, a 1240.
20. MORGAN DA, RUSCETTI FW, GALLO RC. Selective in vitro growth of T lymphocytes from normal human bone marrow. Science 1976: 193: 1007-1008.
21. WELTE DA, WANG CY, MERTELSMANN R, VENUTA S, MOORE MAS. Purification of human interleukin-2 to apparent homogeneity and its molecular heterogeneity. J Exp Med 1982: 115: 454-464.
22. ROSENBERG SA, LOTZE MT, MUUL LM, et al. A progress report on the treatment of 157 patients with advanced cancer using lymphokine-activated killer cells and inteleukin-2 or high-dose interleukin-2 alone. N Engl J Med 1987: 316: 889-897.
23. ACKERSTEIN A, KEDAR E, SLAVIN S. Use of recombinant human interleukin-2 in conjunction with syngeneic bone marrow transplantation in mice as a model for control of minimal residual disease in malignant hematologic disorders. Blood 1991: 78: 1212-1215.
24. ATZPODIEN J, KIRCHNER H, KORFER A, et al. Expansion of peripheral blood natural killer cells correlates with clinical outcome in cancer patients receiving recombinant subcutaneous interleukin-2 and interferon-α2. Tumor Biol 1993: 14: 354-359.
25. FARACE F, ANGEVIN E, DIETRICH PY, et al. Low-dose IL-2 treatment: activation of discrete T- and NK-cell sub-populations in vivo. Int J Cancer 1995: 62: 523-528.
26. BOCCOLI G, MASCIULLI R, RUGGERI EM, et al. Adoptive immunotherapy of human cancer. The cytokine cascade and monocyte activation following high-dose interleukin 2 bolus treatment. Cancer Res 1990: 50: 5795-5800.
27. HESLOP HE, DUNCOMBE AS, REITTIE JE, et al. Interleukin-2 infusion induces haemopoietic growth factors and modifies marrow regeneration after chemotherapy or autologous marrow transplantation. Br J Haematol 1991: 77: 237-244.
28. SCHAAFSMA MR, FALKENBURG FJH, LANDEGENT JE, et al. In vivo production of interleukin-5, granulocyte-macrophage colony-stimulating factor, macrophage colony-stimulating factor, and interleukin-6 during intravenous administration of high-dose interleukin-2 in cancer patients. Blood 1991: 78: 1981-1987.
29. FABIAN I, KLETTER Y, MOR S, GOLDE DW. Activation of human eosinophil and neutrophil functions by hematopoietic growth factors. Comparison of IL-1, IL-3, IL-5 and GM-CSF. Br J Haematol 1992: 8: 137-143.
30. WEST WH, TAUER KW, YANNELLI JR, et al. Constant infusion recombinant interleukin-2 in adoptive immunotherapy of advanced cancer. N Engl J Med 1987: 316: 898-905.
31. BERNSTEIN ZP, VAICKUS L, FRIEDMAN N, et al. Interleukin-2 lymphokine-activated killer cell therapy of non-Hodgkin's lymphoma and Hodgkin's disease. J Immunother 1991: 10: 141-146.
32. DUGGAN DB, SANTARELLI MT, ZAMKOFF K, et al. A phase II study of recombinant interleukin-2 with or without recombinant interferon-β in non-Hodgkin's lymphoma. A study of the Cancer and Leukemia group B. J Immunother 1992: 12: 115-122.
33. LEVY R, TOURANI JM, ANDRIEU JM. Interleukin-2 therapy with or without lymphokine-activated killer cell infusions for low-grade non-Hodgkin's lymphomas? J Clin Oncol 1992: 10: 1366.
34. WEBER JS, YANG JC, TOPALIAN SL, SCHWARTZENTRUBER DJ, WHITE DE, ROSEMBERG SA. The use of interleukin-2 and lymphokine-activated killer cells for the treatment of patients with non-Hodgkin's lymphoma. J Clin Oncol 1992: 10: 33-40.
35. GISSELBRECHT C, MARANINCHI D, PICO JL, et al. Interleukin-2 treatment in lymphoma: a phase II multicenter study. Blood 1994, 83: 2081-2085.
36. HIGUCHI CM, THOMPSON JA, PETERSEN FB, BUCKNER CD, FEFER A. Toxicity and Immunomodulatory effects of Interleukin-2 after autologous bone marrow transplantation for hematologic malignancies. Blood 1991: 77: 2561-2568.
37. SOIFFER RJ, MURRAY C, COCHRAN K, et al. Clinical and immunologic effects of prolonged infusion of low-dose recombinant interleukin-2 after autologous and T-cell-depleted allogeneic bone marrow transplantation. Blood 1992: 79: 517-526.
38. KLAPHOLZ L, ACKERSTETN A, GOLDENHERSH MA, VARDY D, NAGLER A. Local cutaneous reaction induced by subcutaneous interleukin-2 and interferon alpha-2a immunotherapy following ABMT. Bone Marrow Trans 1993: 11: 443-446.
39. FABIAN I, KRAVTSOV V, ELIS A, et al. Eosinophils activation in post-autologous bone marrow transplanted patients treated with subcutaneous interleukin-2 and interferon-α2A immunotherapy. Leukemia 1994: 8: 1379-1384.
40. BENYUNES MC, HIGUCHI C, YORK A, et al. Immunotherapy with interleukin 2 with or without lymphokine activated killer cells after autologous bone marrow transplantation for malignant lymphoma: a feasibility trial. Bone Marrow Trans 1995: 16: 283-288.
41. HANNINEN EL, KORFER A, HADAM M, et al. Biological monitoring of low-dose interleukin 2 in humans: soluble interleukin-2 receptors, cytokines and cell surface phenotypes. Cancer Res 1991: 51: 6312-6316.
42. BOYUM A. Separation of leukocytes from blood and bone marrow. Scand J Clin Lab Invest 1968: 97 (suppl 21 ): 77-89.
43. VELARDI A, VARESE P, GROSSI CE, et al. Cytolytic function of clonable T cells after human bone marrow transplantation. Blood 1990: 75: 1364-1369.